MagVenture receives CE approvals for noninvasive brain treatment of addiction, OCD, and depression with anxiety symptoms
Retrieved on:
Wednesday, April 28, 2021
b'COPENHAGEN, Denmark, April 28, 2021 /PRNewswire/ -- Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD).
Key Points:
- b'COPENHAGEN, Denmark, April 28, 2021 /PRNewswire/ -- Global MedTech pioneer MagVenture has received CE approval for the treatment of addiction and Obsessive-Compulsive Disorder (OCD).
- In addition, MagVenture TMS Therapy can reduce the symptoms of comorbid anxiety in patients suffering from depression.
- "\nFor OCD, a 45% response rate was reported for the group receiving treatment, compared to 18% in the sham group.
- "\nFor subjects responding to the treatment of MDD, who have symptoms of comorbid anxiety, the clinical benefit can additionally include an improvement of anxiety symptoms.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/magventure-receives-ce-approvals...\n'